-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 30, 2021, AstraZeneca announced that the U.
In 2020, approximately 2.
BRCA is an important protein to repair cell DNA damage, and PARP also plays an important role in repairing DNA damage
Previously, it has been approved by the US FDA to treat advanced ovarian cancer, breast cancer, pancreatic cancer and other cancer types that carry germline BRCA mutations
This priority review qualification is awarded based on the positive results obtained in a phase 3 clinical trial
Reference materials:
[1] LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer.